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Type 1 diabetes mellitus (Tl D) is caused by the autoimmune destruction of the insulin 
producing pancreatic beta (p)-cells. Current treatment is by multiple daily insulin 
injections, which cannot mimic the minute-to-minute responsiveness of P-cells in vivo, 
leading to the development of chronic complications, which increase morbidity and 
mortality. This study investigated the use of lentiviral vectors to deliver the furin-cleavable 
proinsulin gene (INS-FUR) to liver cells with the goal of generating glucose-responsive, 
insulin secreting surrogate ~-cells. 
A methodology for viral titre determination ustng flow cytometry was developed, 
optimised and validated. This protocol was cotnpared to the use of fluorescence microscopy 
for titre determination. The latter underestimated the viral titre as accurate quantification of 
transduced cells (enhanced green fluorescent protein (EGFP)-positive) was not possible due 
to the inability to count individual cells, which were in confluent monolayer clusters. 
Furthermore, cells transduced using a low multiplicity of infection (MOl; a ratio of viral 
infectious particles per cell) were indistinguishable from background fluorescence, while 
high MOI significantly underestimated the true functional viral titre. Flow cyton1etry 
enabled the determination of single or low MOJ events and thus increased the accuracy of 
the viral titre determination. 
The second aim of the study was to examine liver tissue from spontaneous diabetic non-
obese diabetic (NOD) mice, which had normalised their blood glucose following the 
delivery of furin-cleavable insulin in the HIV/murine stem cell virus promoter/enhancer 
hybrid (HMD) lentiviral vector (HMD/INS-FUR), for evidence of pancreatic transcription 
factors and hormones, indicative of liver to pancreas transdifferentiation. The HMD/INS-
FUR-treated NOD mice normalised blood glucose levels 24 h after viral vector delivery 
and normoglycaemia was maintained for 150 days (experimental end point). The 
transduced liver tissue showed the presence of insulin storage granules and the expression 
of several pancreatic transcription factors and hormones, including Pdx-1, Neurad .I, Ngn3, 
Pax 4, Nkx2.2, glucagon and somatostatin. Furthermore, the induction of mouse insulin 1 
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expression was detected and this phenomenon may be attributable to the expression of 
MafA and MajB transcription factors, which are known to play crucial roles in insulin 
expression late in the hierarchy of ~-cell maturation. These results indicated that the 
delivery HMD/INS-FUR lentiviral vector to liver tissue induces hepatocyte to ~-cell 
transdifferentiation and therefore holds therapeutic potential for the reversal of autoimmune 
TID. 
The final aim of this study investigated lentiviral vector construct design, and compared the 
HMD/INS-FUR vector construct with the newly acquired WPT/INS-FUR lentiviral 
construct, which possessed the elongation factor 1-alpha promoter with the woodchuck 
hepatitis virus post-transcriptional regulatory element enhancer (WPT). The ability of each 
lentiviral vector to transduce the Huh7 liver cell line using various MOl, insulin secretion, 
storage and glucose-regulated secretion were compared. Huh7 cells were readilty 
transduced with the HMD/INS-FUR vector at an MOl of 75, however attempts at 
transducing the cells with the WPT/INS-FUR vector at an MOl >50, resulted in inhibition 
of cell growth. This was not the case with the empty-WPT vector, which implies the INS-
FUR gene expressed in this vector putatively inhibited metabolic cell function at the higher 
MOl of 75. Insulin secretion was the same irrespective of the l\101 used to transduce the 
Huh7 cells. By comparison, the WPT/INS-FUR viral vector-transduced cells stored a 
significantly higher concentration of insulin when compared to cells transduced with the 50 
and 75 MOl of the HMD/INS-FUR viral vector (p < 0.0001 and p = 0.001, respectively). 
Therefore, fewer viral particles of the WPT/INS-FUR virus were required to achieve 
similar insulin secretion concentrations as the HMD/INS-FUR virus, while also achieving a 
higher concentration of insulin storage. However, as the total level of insulin stored after 
transfection with the WPT/INS-FUR viral vector was low (0.386 ± 0.041 pmoles/106 cells), 
these results must be viewed with caution. 
Overall, this study has optimised an appropriate methodology for the accurate 
determination of viral titre for downstream applications. Furthermore, the study 
dernonstrated the NOD mice transduced with the HMD/INS-FUR viral vector have the 
ability to store and secrete insulin in a glucose-regulated manner, through the induction of 
XVlll 
pancreatic P-cell transcription factors and hormones. Moreover, the WPT/INS-FUR viral 
vector was found to be comparable to HMD/INS-FUR viral vector with respect to insulin 
secretion. However, as the former stored significantly more insulin in vitro, this suggests 
that the WPT /INS-FUR viral vector may be a useful construct for future in vivo studies 
investigating the reversal ofTlD in NOD mice via hepatocyte transduction. 
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